Novo Nordisk A/S (NVO) Stock Forecast & Price Target

Novo Nordisk A/S
Bear Case

Investors should be bearish about investing in Novo Nordisk for these reasons:

• Intensifying competition from Eli Lilly, pricing pressure, and concerns about near-term demand are weighing on the shares, with the stock down 11% in a month, reflecting a lack of near-term growth visibility.
• Erste Group Bank lowered its FY2026 EPS estimate to $3.29 from $3.43 and its FY2027 forecast to $3.25 from $3.32, both below the current consensus estimate, reinforcing concerns about earnings momentum.
• Novo Nordisk's pipeline may not deliver enough growth to offset slowing visibility in its core franchise, with investors questioning the company's ability to maintain its market position in the face of competition.
• The company's valuation, revenue concentration, and dependence on the product pipeline remain important risks, with analysts highlighting the trade-off between its strong market position and potential challenges.
• Novo Nordisk's stock has a beta of 0.76, indicating it is less volatile than the overall market, but this also means it may not benefit as much from market rallies, and its 50-day moving average of $43.13 is above its current price, suggesting a potential downtrend.